An analysis of the attrition of drug candidates from four major pharmaceutical companies
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
The pharmaceutical industry remains under huge pressure to address the high attrition rates in drug development. Attempts to reduce the number of efficacy- and safety-related failures by analysing possible links to the physicochemical properties of small-molecule drug candidates have been inconclusive because of the limited size of data sets from individual companies. Here, we describe the compilation and analysis of combined data on the attrition of drug candidates from AstraZeneca, Eli Lilly and Company, GlaxoSmithKline and Pfizer. The analysis reaffirms that control of physicochemical properties during compound optimization is beneficial in identifying compounds of candidate drug quality and indicates for the first time a link between the physicochemical properties of compounds and clinical failure due to safety issues. The results also suggest that further control of physicochemical properties is unlikely to have a significant effect on attrition rates and that additional work is required to address safety-related failures. Further cross-company collaborations will be crucial to future progress in this area.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Advancing drug safety assessment relies on bridging the translation gap between animal toxicology findings and clinical outcomes, a challenge with far-reaching consequences for R&D efficiency, regulatory success and patient safety (Waring et al., 2015; Amorim et al., 2024).”
From A large-scale concordance study of toxicity findings across preclinical species and humans for small molecules and biologics (2026) · cites this paper as Waring et al., 2015
In the citing paper
“When using a polylactic acid–polyethylene glycol copolymer, the embedding rate reached 90%.”
From Synthesis and Biological Application of Polylactic Acid (2020) · cites this paper as [87]
In the citing paper
“Su et al. found that, when polylactic acid was used as the membrane material, the embedding rate of hemoglobin was very low, only 7.9%.”
From Synthesis and Biological Application of Polylactic Acid (2020) · cites this paper as [87]
In the citing paper
“The attrition rates in Phase II and Phase III development stages have been reported to be as high as 80% [75,344].”
From Cardiovascular disease models: A game changing paradigm in drug discovery and screening (2019) · cites this paper as [75]
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success
Lovering, F., Bikker, J., & Humblet, C. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm901241e · Cited by 4,495
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Drug-like properties and the causes of poor solubility and poor permeability
Lipinski, C. A. (2000) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/s1056-8719(00)00107-6 · Cited by 3,734
Clinical development success rates for investigational drugs
Hay, M., Thomas, D. W., Craighead, J. L., Economides, C., & Rosenthal, J. (2014) · Nature Biotechnology · doi:10.1038/nbt.2786 · Cited by 2,536
The influence of drug-like concepts on decision-making in medicinal chemistry
Leeson, P. D., & Springthorpe, B. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2445 · Cited by 2,403
Self-citationLessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
Cook, D., Brown, D., Alexander, R., March, R., Morgan, P., Satterthwaite, G., & Pangalos, M. N. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4309 · Cited by 1,344
Generation of a Set of Simple, Interpretable ADMET Rules of Thumb
Gleeson, M. P. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701122q · Cited by 969
Physiochemical drug properties associated with in vivo toxicological outcomes
Hughes, J. D., Blagg, J., Price, D. A., Bailey, S., DeCrescenzo, G. A., Devraj, R. V., Ellsworth, E., Fobian, Y. M., Gibbs, M. E., Gilles, R. W., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.07.071 · Cited by 946
Lipophilicity in drug discovery
Waring, M. J. (2010) · Expert Opinion on Drug Discovery · doi:10.1517/17460441003605098 · Cited by 873
Self-citation
Cited by
Items 601–700 of 1,001
Pharmacological Approaches to Hearing Loss
Cederroth, C. R., Dyhrfjeld‐Johnsen, J., & Canlon, B. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.124.001195 · Cited by 18
Wing, K. D. (2016) · Pest Management Science · doi:10.1002/ps.4311 · Cited by 18
Systems biology and network pharmacology of frailty reveal novel epigenetic targets and mechanisms
Gómez-Verján, J. C., Ramírez‐Aldana, R., Pérez‐Zepeda, M. U., Quiroz‐Baez, R., Luna‐López, A., & Gutiérrez‐Robledo, L. M. (2019) · Scientific Reports · doi:10.1038/s41598-019-47087-7 · Cited by 18
A toolkit of methods of development-focused health technology assessment
Bouttell, J., Briggs, A. H., & Hawkins, N. (2021) · International Journal of Technology Assessment in Health Care · doi:10.1017/s0266462321000507 · Cited by 18
Adetutu, A., Olaniyi, T. D., & Owoade, A. O. (2021) · Informatics in Medicine Unlocked · doi:10.1016/j.imu.2021.100722 · Cited by 18
Shave, S., McGuire, K., Pham, N. T., Mole, D. J., Webster, S. P., & Auer, M. (2018) · ACS Omega · doi:10.1021/acsomega.7b02091 · Cited by 18
Wang, Y., Moussian, B., Schaeffeler, E., Schwab, M. G., & Nies, A. T. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.06.002 · Cited by 18
In vitro screening of cell bioenergetics to assess mitochondrial dysfunction in drug development
Tilmant, K., Gerets, H. H. J., Ron, P. D., Hanon, É., Bento‐Pereira, C., & Atienzar, F. (2018) · Toxicology in Vitro · doi:10.1016/j.tiv.2018.07.012 · Cited by 18
Morelló, J., Derks, R. J. E., Lopes, S. S., Steenvoorden, E., Monteiro, E. C., Mayboroda, O. A., & Pereira, S. A. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01193 · Cited by 18
Bajželj, B., & Drgan, V. (2020) · Molecules · doi:10.3390/molecules25030481 · Cited by 18
Zebrafish for modeling stroke and their applicability for drug discovery and development
Crilly, S., McMahon, E., & Kasher, P. R. (2022) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2022.2072828 · Cited by 17
Vrbanac, J., & Slauter, R. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-85704-8.00010-4 · Cited by 17
Telukuntla, P., Chandrakanth, M., Amrutha, P. G., Thomas, N. M., Gondru, R., Valluru, K. R., & Banothu, J. (2024) · Tetrahedron Letters · doi:10.1016/j.tetlet.2024.155180 · Cited by 17
Hepatic transporter drug-drug interactions: an evaluation of approaches and methodologies
Williamson, B., & Riley, R. J. (2017) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2017.1404028 · Cited by 17
Challenges of antibacterial drug discovery
Reck, F., Jansen, J. M., & Moser, H. E. (2019) · ARKIVOC · doi:10.24820/ark.5550190.p010.955 · Cited by 17
Toxicity Screens in Human Retinal Organoids for Pharmaceutical Discovery
Eade, K., Giles, S., Harkins-Perry, S. R., & Friedlander, M. (2021) · Journal of Visualized Experiments · doi:10.3791/62269 · Cited by 17
Recycled Translation: Repurposing Drugs for Stroke
Spellicy, S. E., & Hess, D. C. (2022) · Translational Stroke Research · doi:10.1007/s12975-022-01000-z · Cited by 17
Ahmed, N., Spears, R. J., Sheppard, T. D., & Chudasama, V. (2022) · Chemical Science · doi:10.1039/d2sc01626e · Cited by 17
Sánchez-Ruiz, A., & Colmenarejo, G. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.2c00888 · Cited by 17
Combining DELs and machine learning for toxicology prediction
Blay, V., Li, X., Gerlach, J., Urbina, F., & Ekins, S. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.103351 · Cited by 17
Organ-On-A-Chip Database Revealed—Achieving the Human Avatar in Silicon
Jiang, L., Li, Q., Liang, W., Du, X., Yang, Y., Zhang, Z., Xu, L., Zhang, J., Li, J., Chen, Z., et al. (2022) · Bioengineering · doi:10.3390/bioengineering9110685 · Cited by 17
Identifying multiscale translational safety biomarkers using a network-based systems approach
Callegaro, G., Schimming, J. P., Piñero, J., Kunnen, S. J., Wijaya, L. S., Trairatphisan, P., van den Berk, L., Beetsma, K., Furlong, L. I., Sutherland, J. J., et al. (2023) · iScience · doi:10.1016/j.isci.2023.106094 · Cited by 17
El‐Metwally, S. A., Abuelkhir, A. A., Elkady, H., Taghour, M. S., Ibrahim, I. M., Husein, D. Z., Alsfouk, A. A., Sultan, A. M., Ismail, A., Elkhawaga, S. Y., et al. (2023) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2023.107928 · Cited by 17
Inhibitory effects and mechanism of dihydroberberine on hERG channels expressed in HEK293 cells
Yu, D., Lv, L. L., Li, F., Zhang, B., Wang, J., Zhan, G., Zhao, L., Zhao, X. Y., & Li, B. (2017) · PLoS ONE · doi:10.1371/journal.pone.0181823 · Cited by 17
Self-citationScreening of the NIH Clinical Collection for inhibitors of HIV-1 integrase activity
Abrahams, S., Mosebi, S., Fish, M. Q., Papathanasopoulos, M. A., & Hewer, R. (2018) · South African Journal of Science · doi:10.17159/sajs.2018/20170324 · Cited by 17
Norinder, U., Ahlberg, E., & Carlsson, L. (2018) · Mutagenesis · doi:10.1093/mutage/gey038 · Cited by 17
The expanding utility of microdosing
Lappin, G. (2015) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.235 · Cited by 17
Comparison of metabolic pathways of different α-N-heterocyclic thiosemicarbazones
Pelivan, K., Frensemeier, L. M., Kärst, U., Koellensperger, G., Heffeter, P., Keppler, B. K., & Kowol, C. R. (2018) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-018-0889-x · Cited by 17
Fabini, E., Tramarin, A., & Bartolini, M. (2018) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2018.03.060 · Cited by 17
Drug Discovery and Development for Kinetoplastid Diseases
Caffrey, C. R., Steverding, D., Ferreira, R. S., de Oliveira, R. B., O’Donoghue, A. J., Monti, L., Ballatore, C., Bachovchin, K. A., Ferrins, L., Pollastri, M. P., et al. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc235.pub2 · Cited by 17
Sandhya, A., Shieh, C., Horng, M., Radhakrishnan, S. V., Radhakrishnan, S., & Omri, A. (2026) · Drug Discovery Today · doi:10.1016/j.drudis.2026.104602 · Cited by 16
Using Human Genetics to Drive Drug Discovery: A Perspective
Fox, C. S. (2019) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2018.12.045 · Cited by 16
PACIA: Parameter-Efficient Adapter for Few-Shot Molecular Property Prediction
Wu, S., Wang, Y., & Yao, Q. (2024) · International Joint Conference on Artificial Intelligence · doi:10.24963/ijcai.2024/576 · Cited by 16
Industry Perspective on Biomarker Development and Qualification
Gerlach, C. V., Derzi, M., Ramaiah, S. K., & Vaidya, V. S. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.919 · Cited by 16
Barber, J., Sikakana, P., Sadler, C., Baud, D., Valentin, J., & Roberts, R. A. (2020) · Toxicology Research · doi:10.1093/toxres/tfaa106 · Cited by 16
Burt, T., Roffel, A. F., Langer, O., Anderson, K., & DiMasi, J. A. (2022) · Clinical and Translational Science · doi:10.1111/cts.13269 · Cited by 16
Karimi-Jafari, M., Ziaee, A., O’Reilly, E. J., Croker, D. M., & Walker, G. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14030634 · Cited by 16
Non-destructive monitoring of 3D cell cultures: new technologies and applications
Cortesi, M., & Giordano, E. (2022) · PeerJ · doi:10.7717/peerj.13338 · Cited by 16
Prediction of drug side effects with transductive matrix co-completion
Liang, X., Fu, Y., Qu, L., Zhang, P., & Chen, Y. (2023) · Bioinformatics · doi:10.1093/bioinformatics/btad006 · Cited by 16
Discovery of New VEGFR-2 Inhibitors and Apoptosis inducer-based thieno[2,3- d ]pyrimidine
El‐Metwally, S. A., Elkady, H., Hagras, M., Elkaeed, E. B., Alsfouk, B. A. A., Doghish, A. S., Ibrahim, I. M., Taghour, M. S., Husein, D. Z., Metwaly, A. M., et al. (2023) · Future Medicinal Chemistry · doi:10.4155/fmc-2023-0130 · Cited by 16
Data Standardization, Pharmaceutical Drug Development, and the 3Rs
Kaufman, L. S., Gore, K., & Zandee, J. (2016) · ILAR Journal · doi:10.1093/ilar/ilw030 · Cited by 16
The pharmacokinetics and metabolism of diclofenac in chimeric humanized and murinized FRG mice
Wilson, C. E., Dickie, A. P., Schreiter, K., Wehr, R., Wilson, E. M., Bial, J., Scheer, N., Wilson, I. D., & Riley, R. J. (2018) · Archives of Toxicology · doi:10.1007/s00204-018-2212-1 · Cited by 16
Allen, C. H. G., Mervin, L., Mahmoud, S. Y., & Bender, A. (2019) · Journal of Cheminformatics · doi:10.1186/s13321-019-0356-5 · Cited by 16
Lv, K., Wang, A., Tao, Z., Fu, L., Liu, H., Wang, B., Ma, C., Wang, H., Ma, X., Han, B., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.06.053 · Cited by 16
Briand, E., Thomsen, R., Línnet, K., Rasmussen, H. B., Brunak, S., & Taboureau, O. (2019) · Molecules · doi:10.3390/molecules24152747 · Cited by 16
Yang, Y., Zhang, Y., Hua, Y., Chen, X., Fan, Y., Wang, Y., Liang, L., Deng, C., Lu, T., Chen, Y., et al. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.9b00841 · Cited by 16
Howard, M., Barber, J., Alizai, N. K., & Rostami‐Hodjegan, A. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1546288 · Cited by 16
Patel, D. D., Antoni, C., Freedman, S. J., Levesque, M. C., & Sundy, J. S. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.04.029 · Cited by 16
Erratum: Drug discovery effectiveness from the standpoint of therapeutic mechanisms and indications
Shih, H.-P., Zhang, X., & Aronov, A. M. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.255 · Cited by 15
Bayrak, S., Gerni, S., Öztürk, C., Bakan, B., Elmas, Ş., & M.Aliyeva, A. T. M. H. D. N. (2025) · Food Biophysics · doi:10.1007/s11483-025-10034-3 · Cited by 15
Tanihata, S., & Iwata, H. (2026) · Yonago acta medica · doi:10.33160/yam.2026.02.001 · Cited by 15
Drug Development Failure from Preclinical, Clinical, and Industrial Perspectives
Dsouza, A. M. (2026) · Journal of Integrative and Translational Biomedicine · doi:10.67316/jintb.v1.i2.20 · Cited by 15
A data-driven machine learning approach for discovering potent LasR inhibitors
Koh, C. M. M., Ping, L. S. Y., Xuan, C. H. H., Theng, L. B., San, H. S., Palombo, E. A., & Wezen, X. C. (2023) · Bioengineered · doi:10.1080/21655979.2023.2243416 · Cited by 15
STOPLIGHT: A Hit Scoring Calculator
Wellnitz, J., Martin, H., Hossain, M. A., Rath, M. K., Fox, C., Popov, K. I., Willson, T. M., Muratov, E. N., & Tropsha, A. (2024) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.4c00412 · Cited by 15
Mohammed, M., & Adnan, A. A. (2024) · Turkish computational and theoretical chemistry/Turkish computational and theoretical chemistry : · doi:10.33435/tcandtc.1355772 · Cited by 15
Application of Big Data and Artificial Intelligence in The RESEARCH of Health Functional Foods
Hong, J., & Kim, Y. J. (2024) · Food Supplements and Biomaterials for Health · doi:10.52361/fsbh.2024.4.e19 · Cited by 15
Walker, A., Walgama, C. T., Nerimetla, R., Alavi, S. H., Echeverría, E., Harimkar, S. P., McIlroy, D. N., & Krishnan, S. (2020) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2020.110790 · Cited by 15
Development of an adverse drug event network to predict drug toxicity
Wu, Q., Taboureau, O., & Audouze, K. (2020) · Current Research in Toxicology · doi:10.1016/j.crtox.2020.06.001 · Cited by 15
Advanced Non-animal Models in Biomedical Research: Respiratory Tract Diseases
Jarlath, H., Lindsay, M., Adcock, I. M., Tomas, N., Nič, M., Dibusz, K., Gribaldo, L., & Maurice, W. (2020) · Joint Research Centre (European Commission) · doi:10.2760/725821 · Cited by 15
Application of in Silico Technologies for Drug Target Discovery and Pharmacokinetic Analysis
Iwata, H. (2023) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c22-00638 · Cited by 15
Leveraging nitrogen occurrence in approved drugs to identify structural patterns
Masand, V. H., Al‐Hussain, S. A., Alzahrani, A. Y. A., El-Sayed, N. N. E., Yeo, C. I., Tan, Y. S., & Zaki, M. E. A. (2023) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2023.2266990 · Cited by 15
Advancements in Preclinical Models of Pancreatic Cancer
Salu, P., & Reindl, K. M. (2024) · Pancreas · doi:10.1097/mpa.0000000000002277 · Cited by 15
The impact of early human data on clinical development: there is time to win
Swart, P., Lozac’h, F., Simon, M., van Duijn, E., & Vaes, W. H. J. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.03.012 · Cited by 15
Falcão, V. C. A., Villela, A. D., Rodrigues-Junior, V. S., Pissinate, K., Eichler, P., Pinto, A. F. M., Basso, L. A., Santos, D. S., & Bizarro, C. V. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.02.137 · Cited by 15
Nemani, K. S., Shard, A., & Sengupta, P. (2018) · Journal of Chromatography B · doi:10.1016/j.jchromb.2018.08.019 · Cited by 15
Russo, G., Barbato, F., Grumetto, L., Philippe, L., Lynen, F., & Goetz, G. H. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.02.008 · Cited by 15
Srilatha, M., Patyal, N., & Saddala, M. S. (2020) · Journal of Integrative Agriculture · doi:10.1016/s2095-3119(19)62813-3 · Cited by 15
QM Calculations in ADMET Prediction
Pozzan, A. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-0282-9_18 · Cited by 15
Jörg, M., & Madden, K. S. (2021) · RSC Medicinal Chemistry · doi:10.1039/d1md00022e · Cited by 15
Pharmacokinetic characterization of drugs and new product development
Chatterjee, B., Sengupta, P., & Tekade, R. K. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-814425-1.00010-3 · Cited by 15
Library size in virtual screening: is it truly a number’s game?
Kontoyianni, M. (2022) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2022.2130244 · Cited by 15
Myszczyszyn, A., Muench, A., Lehmann, V., Sinnige, T., van Steenbeek, F. G., Bouwmeester, M., Samsom, R.-A., Keuper-Navis, M., van der Made, T. K., Kogan, D., et al. (2025) · Biofabrication · doi:10.1088/1758-5090/adc3ce · Cited by 14
El‐Metwally, S. A., Omara, M., Elkady, H., Elkaeed, E. B., Al-Ghulikah, H., Taghour, M. S., El‐Mahdy, H. A., Ibrahim, I. M., Husein, D. Z., Metwaly, A. M., et al. (2024) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2023.137465 · Cited by 14
TAK-994 mechanistic investigation into drug-induced liver injury
Shinozawa, T., Miyamoto, K., Baker, K. S., Faber, S. C., Flores, R., Uetrecht, J., von Hehn, C., Yukawa, T., Tohyama, K., Kadali, H., et al. (2025) · Toxicological Sciences · doi:10.1093/toxsci/kfaf003 · Cited by 14
The Logic of Chemical Optimization
Kombo, D. C., & LaMarche, M. J. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00445 · Cited by 14
Network‐based precision medicine and systems pharmacology
Pandey, A. K., Ghiassian, S. D., & Loscalzo, J. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70184 · Cited by 14
Organ‐on‐a‐Chip Technology and Global Multi‐Omics: Current Applications and Future Directions
Cao, X., Xia, C., Li, C., Deng, S., Cao, J., Yang, H., Wang, S., & Chen, P. (2026) · MedComm · doi:10.1002/mco2.70603 · Cited by 14
Ingelman-Sundberg, M., & Lauschke, V. M. (2018) · Pharmacogenomics · doi:10.2217/pgs-2018-0096 · Cited by 14
Canning, P., Birchall, K., Kettleborough, C. A., Merritt, A. T., & Coombs, P. J. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.09.003 · Cited by 14
Natural Products, the Fourth Industrial Revolution, and the Quintuple Helix
Daley, S.-K., & Cordell, G. A. (2021) · Natural Product Communications · doi:10.1177/1934578x211003029 · Cited by 14
High-Throughput Detection of Ligand-Protein Binding Using a SplitLuc Cellular Thermal Shift Assay
Sanchez, T. W., Owens, A. E., Martinez, N. J., Wallgren, E., Simeonov, A. M., & Henderson, M. J. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1665-9_2 · Cited by 14
Recent advances in Fragment-based strategies against tuberculosis
Villemagne, B., Faïon, L., Tangara, S., & Willand, N. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115569 · Cited by 14
Lee, B., Nanishi, E., Levy, O., & Dowling, D. J. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15061766 · Cited by 14
Live cell painting: New nontoxic dye to probe cell physiology in high content screening
Cottet, M., Fernández‐Marrero, Y., Mathien, S., Audette, K., Lambert, R., Bonneil, É., Chng, K., Campos, A., & Andrews, D. W. (2023) · SLAS DISCOVERY · doi:10.1016/j.slasd.2023.10.005 · Cited by 14
Role of ADME/PK in Drug Discovery, Safety Assessment, and Clinical Development
White, R. E. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12364-9 · Cited by 14
Amine promiscuity and toxicology analysis
Lee, E. C. Y., Steeno, G. S., Wassermann, A. M., Zhang, L., Shah, F., & Price, D. A. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.11.085 · Cited by 14
Out‐compute drug side effects: Focus on cytochrome P450 2D6 modeling
Don, C. G., & Smieško, M. (2018) · Wiley Interdisciplinary Reviews Computational Molecular Science · doi:10.1002/wcms.1366 · Cited by 14
Small-Scale Panel Comprising Diverse Gene Family Targets To Evaluate Compound Promiscuity
Sameshima, T., Yukawa, T., Hirozane, Y., Yoshikawa, M., Katoh, T., Hara, H., Yogo, T., Miyahisa, I., Okuda, T., Miyamoto, M., et al. (2019) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.9b00128 · Cited by 14
Brereton, A. E., MacKinnon, S. S., Safikhani, Z., Reeves, S., Alwash, S., Shahani, V. M., & Windemuth, A. (2020) · Machine Learning Science and Technology · doi:10.1088/2632-2153/ab891b · Cited by 14
Burton, L., Scaife, P. J., Paine, S. W., Mellor, H. R., Abernethy, L., Littlewood, P., & Rauch, C. (2020) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00472.2019 · Cited by 14
Porcine cancer models: potential tools to enhance cancer drug trials
Robertson, N., Schook, L. B., & Schachtschneider, K. M. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1757644 · Cited by 14
Russell, L. E., Schleiff, M. A., Gonzalez, E. R., Bart, A. G., Broccatelli, F., Hartman, J. H., Humphreys, W. G., Lauschke, V. M., Martin, I. J., Nwabufo, C. K., et al. (2020) · Drug Metabolism Reviews · doi:10.1080/03602532.2020.1765793 · Cited by 14
Xu, J., Wang, Y., Kauffman, A. E., Zhang, Y., Li, Y., Zhu, J., Maratea, K. A., Fabre, K. M., Zhang, Q., Woodruff, T. K., et al. (2020) · Toxicological Sciences · doi:10.1093/toxsci/kfaa118 · Cited by 14
Oebbeke, M., Siefker, C., Wagner, B., Heine, A., & Klebe, G. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202011295 · Cited by 14
Bugs on Drugs: A Drosophila melanogaster Gut Model to Study In Vivo Antibiotic Tolerance of E. coli
den Bergh, B. V. (2022) · Microorganisms · doi:10.3390/microorganisms10010119 · Cited by 14
Park, Y. M., Dahlem, C., Meyer, M. R., Kiemer, A. K., Müller, R., & Herrmann, J. E. (2022) · Molecules · doi:10.3390/molecules27041290 · Cited by 14
Heinzke, A. L., Zdrazil, B., Leeson, P. D., Young, R. J., Pahl, A., Waldmann, H., & Leach, A. R. (2024) · Scientific Data · doi:10.1038/s41597-024-03582-9 · Cited by 14
Self-citationFROGENT: An End-to-End Full-process Drug Design Multi-Agent SystemPreprint
Pan, Q., Xu, D., Yang, Q., Yao, J. X., Yuan, S., Zhu, Z., Li, J., & Ji, J. (2025) · arXiv (Cornell University) · doi:10.48550/arxiv.2508.10760 · Cited by 14
A cross-disease, pleiotropy-driven approach for therapeutic target prioritization and evaluation
Bao, C., Tan, T., Wang, S., Gao, C., Lu, C., Yang, S., Diao, Y., Jiang, L., Jing, D., Chen, L., et al. (2024) · Cell Reports Methods · doi:10.1016/j.crmeth.2024.100757 · Cited by 13
Yang, Z., Yu, J. Q., & Wong, C. C. (2024) · Cells · doi:10.3390/cells13161312 · Cited by 13
Metadata
- Authors
- Waring, M. J., Arrowsmith, J., Leach, A. R., Leeson, P. D., Mandrell, S., Owen, R. M., Pairaudeau, G., Pennie, W. D., Pickett, S. D., Wang, J., Wallace, O., & Weir, A.
- Affiliations
- AstraZeneca (United Kingdom) (GB)
- Thomson Reuters (United Kingdom) (GB)
- GlaxoSmithKline (United Kingdom) (GB)
- Pfizer (United Kingdom) (GB)
- Eli Lilly (United States) (US)
- Corresponding author
- Waring, Michael J.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2015-06-19
- Volume
- 14
- Issue
- 7
- Pages
- 475-486
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1663154925
- Cited by
- 1,450
- References
- 27
- Citations by year
- 2026: 164 · 2025: 116 · 2024: 148 · 2023: 143 · 2022: 140 · 2021: 131 · 2020: 129 · 2019: 129 · 2018: 129 · 2017: 113 · 2016: 94 · 2015: 11
- FWCI
- 12.56
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Newcastle University ePrints (Newcastle Univesity)
- Funders
- Pfizer
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
- Keywords
- drug attrition, small molecule drug candidates, physicochemical properties, clinical failure, drug safety, compound optimization, oral medication, pharmaceutical industry
- MeSH terms
- Animals, Drug Industry, Drug Evaluation, Preclinical, Humans, Statistics as Topic, Drugs, Investigational, Drug Delivery Systems, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.